SEC Form 8-K Summary
Business context and reporting period
The filing was submitted by Vallon Pharmaceuticals, Inc., not GRI Bio, Inc., on November 12, 2021. It reports the furnishing of a press release announcing financial results for the quarter ended September 30, 2021, together with a business update.
The filing identifies Vallon Pharmaceuticals as a Delaware corporation listed on the Nasdaq Capital Market under the ticker VLON. The referenced press release is Exhibit 99.1, but its contents are not included in the provided filing text.
Financial results and liquidity
The filing itself does not provide clear values for revenue, net income or loss, cash flow, margins, debt, cash and cash equivalents, liquidity, or other financial metrics. These details may be contained in the referenced Exhibit 99.1, which was not provided.
Material changes versus the prior comparable period
The filing text does not describe specific period-over-period changes. The referenced press release reportedly included financial results and a business update, but no underlying details are available in the provided content.
Guidance, outlook, risks, and unusual items
No guidance, outlook, management commentary, risk factors, contingencies, or unusual items are described in the filing text provided.
The report states that the information, including Exhibit 99.1, was furnished rather than filed under Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings.
Facts investors should verify
- Confirm whether the intended issuer was Vallon Pharmaceuticals, Inc. or GRI Bio, Inc.; the filing identifies Vallon Pharmaceuticals.
- Obtain and review Exhibit 99.1 for the actual quarterly financial results and business update.
- Verify cash balances, operating cash burn, funding needs, debt, and liquidity outlook.
- Review any clinical, regulatory, commercial, or corporate developments discussed in the omitted press release.
- Confirm whether management provided financial or operational guidance for subsequent periods.